FTRE Earnings

FTRE reported its earnings on 2026-02-26, showcasing a revenue of against an estimate of 668.09M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.16 by 0%. The stock experienced a 4.45% price change on the earnings day and a 1.35% change over the next five days, reflecting market reactions to the results.

Following FTRE's earnings announcement on 2026-02-26, the stock price moved by 4.45% on the day of the release. Over the subsequent five days, it saw a 1.35% change. Historically, FTRE's stock price tends to shift by an average of 12.97% in the 10 days leading up to earnings and -1.88% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate FTRE's annual revenue to reach 659.22M, while the EPS is projected at 0.13. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between FTRE's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, FTRE's stock price typically moves by 12.97% in the 10 days before its earnings and -1.88% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.13 and revenue of 659.22M.

The earnings call summary and Q&A indicate a positive outlook. Financial performance shows improvement, with debt repayment and DSO enhancements. Product development is strong, with AI deployment plans and a healthy biotech market. Market strategy is optimistic, with increased RFP flow and stable bookings. Financial health is stable, with cost optimization and debt reduction. Shareholder returns are not explicitly mentioned but implied to be stable. The Q&A confirms positive sentiment, with cautious optimism in biotech and AI's role. Overall, the company's strong financial metrics, optimistic guidance, and operational improvements support a positive stock price prediction.